Paratek Pharmaceuticals Announces Promotion of Evan Loh,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
79
Paratek Pharmaceuticals Announces Promotion of Evan Loh, M.D. to the role of President and Chief Operating Officer

-  Evan Tzanis promoted to Senior Vice President, Clinical Development and Clinical Operations  

-  Jeanne Jew promoted to Senior Vice President, Business Development

BOSTON, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK ), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced today that Evan Loh, M.D. has been promoted to the role of President and Chief Operating Officer. Dr. Loh, who is also a member of Paratek’s board of directors, had served in the role of President and Chief Medical Officer since 2014. He will continue to retain the title of Chief Medical Officer and will continue to report to Michael Bigham, Chief Executive Officer & Chairman.

“Under Evan’s leadership, Paratek has seen remarkable growth and achieved significant clinical success in advancing our lead product candidate towards the market,” said Michael Bigham, Chairman and Chief Executive Officer, Paratek. “Widely respected by Paratek employees and across the pharmaceutical and biotech industry, Evan is an experienced, thoughtful and committed leader.  I have complete confidence in his ability to guide the company as we approach critical clinical and regulatory milestones.”

Additionally, the company announced that Evan Tzanis has been promoted to Senior Vice President, Clinical Development and Clinical Operations. Evan has successfully led clinical development efforts at Paratek since joining Paratek in 2014. Jeanne Jew, who joined Paratek in 2015, has been promoted to Senior Vice President, Business Development. Both Mr. Tzanis and Ms. Jew will report to Evan Loh.

“It is gratifying to recognize the contributions of both these professionals to our company,” said Evan Loh, M.D., President and Chief Operating Officer. “We are fortunate to have talented and experienced individuals throughout our organization. The expanded roles of both Evan and Jeanne continue to strengthen our leadership team.  We look forward to their future contributions as we move toward prospective NDA approval and commercialization of omadacycline.”

About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria. In June 2016 Paratek announced positive efficacy data in a Phase 3 registration study in ABSSSI demonstrating the efficacy and safety of intravenous (IV) to once-daily oral omadacycline compared to linezolid. A Phase 3 registration study for community acquired bacterial pneumonia (CABP) comparing IV-to-once daily oral omadacycline to IV-to-oral moxifloxacin was initiated in November 2015. Paratek will report top-line data from this study during the second quarter of 2017. A Phase 3 registration study in ABSSSI comparing once-daily oral-only dosing of omadacycline to twice-daily oral-only dosing of linezolid was initiated in August 2016. Top line data are expected as early as the second quarter of 2017. A Phase 1B study in uncomplicated urinary tract infections (UTI) was initiated in May 2016 and positive top-line PK proof-of-principle data was reported in November 2016. Omadacycline has been granted Qualified Infectious Disease Product designation and Fast Track status by the U.S. Food and Drug Administration.

Omadacycline is a new once-daily oral and IV, well-tolerated broad spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections, community acquired bacterial pneumonia, urinary tract infections and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians.

Paratek's second Phase 3 product candidate, sarecycline, is a well-tolerated, once-daily, oral, narrow spectrum tetracycline-derived antibiotic with potent anti-inflammatory properties for the potential treatment of acne and rosacea in the community setting. Allergan owns the U.S. rights for the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights. Allergan initiated two identical Phase 3 registration studies in December 2014 for sarecycline for the treatment of moderate to severe acne vulgaris. Top line data are expected in the first half of 2017.

For more information, visit www.paratekpharma.com . 

Forward Looking Statements This press release contains forward-looking statements including statements related to our overall strategy, product candidates, clinical trials, cash resources, prospects and expected results, including statements about the timing of advancing omadacycline and otherwise preparing for clinical trials, the potential for omadacycline to serve as an empiric monotherapy treatment option for patients suffering from ABSSSI, CABP, UTI, and other bacterial infections when resistance is of concern, the prospect of omadacycline providing broad-spectrum activity, and our having the resources to execute on our clinical trials. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "believe," "expect," "well positioned," "look forward," "anticipated," "continued," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to (i) our need for substantial additional funding to complete the development and commercialization of our product candidates, (ii) our ability to raise the capital to do so, (iii) our ability to develop our drug candidates for potential commercialization, (iv) the advancement of omadacycline Phase 3 trials for ABSSSI and CABP, (v), (v) the potential for omadacycline to be successfully developed for use as a first-line empiric monotherapy for patients suffering from serious community-acquired bacterial infections, (vi) the potential of omadacycline to become the primary antibiotic choice of physicians for the treatment of serious community-acquired bacterial infections, (vii) the ability of our supply chain to provide adequate supply to satisfy our clinical and commercial demand (viii) the potential use and effectiveness of sarecycline for the treatment of acne and rosacea in the community setting, and (ix) the timing of the  Phase 3 program in moderate-severe acne for sarecycline, risks that data to date and trends may not be predictive of future results, risks related to the conduct of our clinical trials, and risks that our clinical trials and product candidates do not receive regulatory approval. These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2015, and our other filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

CONTACTS: Media: Michael Lampe Scient Public Relations (484) 575-5040 michael@scientpr.com Investors: Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 7

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 36

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 146

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
YYForce's Strategic Play: Robotics and AI Expansion

Updated Category News Views 28

Innovation Meets Pragmatism at YYForce There's a new bout of excitement brewing over at YYForce Inc. (NASDAQ: YFOR), if the latest announcements are anything to go by. The Singapore-based AI-enabled workforce dynamo is laying out priorities like a general plotting a campaign—pragmatic, strategic, and with a keen eye on the bottom line. Aiming for a Technological Edge In...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 36

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 102

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Mall of America Strives for World Record This Black Friday

Updated Category News Views 111

History in the Making at Mall of America Yeah, it seems these folks are not just about shopping anymore. The Mall of America is aiming to set the bar high this Black Friday, eyeing a GUINNESS WORLD RECORDS title for the most people holding up the same shopping bag all at once. Imagine a thousand people, synchronized like a flash mob—only with shopping bags instead of...

Continue Reading
SahajMobile's $25M Boost: Impact on Bangladesh Market

Updated Category News Views 42

Untapped Digital Frontier in Bangladesh There's an undeniable buzz around SahajMobile's recent $25 million credit facility, and it's one worth dissecting. This shot of capital, lined up with ALMA as part of SahajMobile’s Series A gamble, is setting the stage for a real shuffle in Bangladesh's digital landscape. Plugging into a Market Gap Ever since it hit the ground...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 13

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 319

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Smart Waste Management Market Growth Insights

Updated Category News Views 124

Overview of the Smart Waste Management Market In recent years, the smart waste management market has garnered substantial attention, projected to transition from $2.2 billion in valuation to an impressive $8.3 billion. This surge reflects a remarkable compound annual growth rate (CAGR) of 15.6% from 2024 to 2032. The driving force behind this growth stems from increasing...

Continue Reading
Exploring the Collaborative Spirit at the China-US Event

Updated Category News Views 150

Celebrating Cultural Connections The recent 'My China Album' event highlighted the importance of cultural exchanges between the United States and China, focusing on the shared journeys and experiences of citizens from both nations. Strengthening Relations through Understanding During this special occasion, the ambassador emphasized the collaborative spirit that can propel...

Continue Reading
Exciting New Active Adult Community Launches in Central Oregon

Updated Category News Views 143

Welcoming Active Adults to Dry Canyon Introducing Dry Canyon, an extraordinary gated community designed specifically for those aged 55 and better. This remarkable development offers active adults a perfect blend of resort-style living and scenic beauty, all nestled in the heart of Central Oregon. As part of this celebration, Lennar, a well-respected name among...

Continue Reading
XTI Aerospace Announces Upcoming Town Hall for Stakeholders

Updated Category News Views 153

XTI Aerospace Invites Stakeholders to Upcoming Town Hall Updates on Tri-Fan 600, Valkyrie AI and Vanguard Platform ENGLEWOOD, Colo. – XTI Aerospace, Inc. (NASDAQ: XTIA) is at the forefront of advancing vertical flight technologies. The company is making exciting progress with its next-generation vertical takeoff and landing (VTOL) aircraft, the TriFan 600. XTI Aerospace...

Continue Reading
Big Lots Launches Discounts and Donations for Vets in November

Updated Category News Views 47

Big Lots Supports Veterans and Active Military with November Campaigns Every November, Big Lots makes a concerted effort to give back to veterans and active military members. This initiative is a part of their commitment to recognizing the sacrifices made by those who serve our country. Highlighting their respect for military service, Big Lots introduces various discounts...

Continue Reading